TLR8
ENSG00000101916
Target class
Membrane receptor
Chromosome
X
Approved drugs
0
Clinical candidates (approved and in development)
7
- Approved drugs
- 0
- Clinical candidates (approved and in development)
- 7
- Chemical probe available
- Yes
- Target name
- TLR8
- Gene name
- Toll like receptor 8
- Gene symbol
- TLR8
- Protein name
- Toll-like receptor 8 (CD antigen CD288)
- CD288
- hTLR8
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Toll like receptors
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 7
- Highest tissue expression
- 44.07
- Tissue specificity (Gini)
- 0.856
- Tissue specificity (tau)
- 0.983
- KEGG gene identifiers
- hsa:51311
- Protein interaction confidence
- 0.798548
- Protein interaction partners
- 42
- R-HSA-1679131
- R-HSA-168181
- R-HSA-9705671
- End position
- 12923169
- Start position
- 12906620
- Chromosome
- X
- Strand
- Forward
- Endosome membrane
- Single-pass type I membrane protein . Note=Endosomal localization confers distinctive proteolytic processing. .
Publication evidence
- PubMed 25297876
- Tissue specificity (tau)
- 0.983243
- Expression inequality (Gini)
- 0.855522
Expression in transcripts per million
- Whole Blood
- 44.07
- Spleen
- 16.94
- Lung
- 5.04
- Adipose - Subcutaneous
- 1.61
- Adipose - Visceral (Omentum)
- 1.4
Expression in transcripts per million
- Whole Blood44.07
- Spleen16.94
- Lung5.04
- Adipose - Subcutaneous1.61
- Adipose - Visceral (Omentum)1.4
- Small Intestine - Terminal Ileum1.25
- Artery - Coronary1.13
- Artery - Aorta0.89
- Nerve - Tibial0.72
- Colon - Transverse0.59
- Cervix - Endocervix0.58
- Bladder0.54
- Breast - Mammary Tissue0.5
- Adrenal Gland0.5
- Colon - Sigmoid0.49
- Artery - Tibial0.46
- Esophagus - Muscularis0.46
- Esophagus - Gastroesophageal Junction0.4
- Minor Salivary Gland0.38
- Fallopian Tube0.35
- Brain - Spinal cord (cervical c-1)0.35
- Thyroid0.31
- Uterus0.3
- Prostate0.27
- Vagina0.27
And 29 more, listed on the interactive page.
- GO:0009615
- GO:0016064
- GO:0032727
- GO:0032728
- GO:0032729
- GO:0032731
- GO:0032757
- GO:0034158
- GO:0043123
- GO:0045089
- GO:0051607
- GO:0071260
- GO:0000139
- GO:0005789
- GO:0009897
- GO:0010008
- GO:0036020
- GO:0003677
- GO:0003723
- GO:0003725
- GO:0003727
- GO:0005515
Related records
Trials (67)
- A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum
- A Clinical Trial to Evaluate the Safety and Immunogenicity of a Prophylactic HIV Vaccine Candidate
- A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV
- A Phase Ib Study of Neoadjuvant of Cetuximab Plus Motolimod and Cetuximab Plus Motolimod Plus Nivolumab
- A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)
- A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female Participants
- A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
- A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)
- A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors
- A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy Participants
- A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of Midazolam
- A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus
- A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants
- A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer
- A Study to Evaluate the Safety and Immunogenicity of 2 Doses of 100µg BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, Given to a Population of Adults Who Have Received 3 Doses of 300µg BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted
- A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy Participants
- A TQT Study to Investigate the Effect of Enpatoran on Cardiac Repolarization in Healthy Participants
- An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy Participants
Drugs (7)
- Afimetoran Toll-like receptor 8 inhibitor
- Bazlitoran Toll-like receptor 8 antagonist
- Enpatoran Toll-like receptor 8 antagonist
- Motolimod Toll-like receptor 8 agonist
- Resiquimod Toll-like receptor 8 agonist
- Selgantolimod Toll-like receptor 8 agonist
- Telratolimod Toll-like receptor 8 agonist